FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

The U.S. Food and Drug Administration, a division within the U.S. Department of Health and Human Services (HHS), today announced the Rare Disease Framework Initiative to reimagine the development of drugs and biologics for rare diseases. As outlined in a new white paper , the Initiative will develop an optimized, fit-for-purpose framework that reflects the realities of rare disease drug development by considering the nuances of each disease, patient needs, product type and the evidence that can be realistically generated in small patient populations.

To solicit feedback on the Rare Disease Framework Initiative from patients and disease advocates, industry, and others, the FDA will host an October 28 meeting at the FDA’s White Oak campus. The meeting will be facilitated by the Reagan-Udall Foundation for the FDA.

“Americans with rare diseases cannot afford a regulatory system that treats every condition the same,” said HHS Secretary Robert F. Kennedy, Jr. “Under President Trump, FDA is rethinking rare disease drug development by putting patients at the center and matching regulatory requirements to the realities of small patient populations. We will remove unnecessary barriers, embrace cutting-edge science, and accelerate promising treatments while upholding FDA’s rigorous standards.”

“Patients and families living with rare diseases have few or no approved treatment options, and the burden of uncertainty can extend across every part of their lives,” said Acting FDA Commissioner Kyle Diamantas, J.D. “As we learn more about rare diseases and better understand the breadth of suffering they cause, we must ensure that America’s regulatory system remains at the forefront — prepared to respond to emerging science, anticipate the needs of patients and families, and help bring safe and effective therapies to those who need them. The FDA will fight hard for patients by building a more consistent, predictable, and innovative approach to rare disease drug development while maintaining the rigorous standards Americans expect from the FDA.”